Cite
Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin's Lymphoma: Results of the Ripple 3-Year Follow-up Study
MLA
Yan, Gao, et al. “Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin’s Lymphoma: Results of the Ripple 3-Year Follow-up Study.” Blood, vol. 142, no. 1, Number 1 Supplement 1, Nov. 2023, p. 4411. EBSCOhost, https://doi.org/10.1182/blood-2023-186099.
APA
Yan, G., Wu, J., Huang, Y., Zhou, H., Feng, R., Li, F., Li, X.-P., Wang, X., Bai, B., Huang, Y.-H., He, H., Ping, L., He, Y., Huang, C., Li, J., Mao, J., & Huang, H. (2023). Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin’s Lymphoma: Results of the Ripple 3-Year Follow-up Study. Blood, 142(1, Number 1 Supplement 1), 4411. https://doi.org/10.1182/blood-2023-186099
Chicago
Yan, Gao, Jianqiu Wu, Yunhong Huang, Hui Zhou, Ru Feng, Fei Li, Xue-Ping Li, et al. 2023. “Novel Chemotherapy-Free Initial Treatment of Rituximab Biosimilar Plus Pegylated Interferon α-2b in Pts with Untreated Advanced Indolent B-Cell Non-Hodgkin’s Lymphoma: Results of the Ripple 3-Year Follow-up Study.” Blood 142 (1, Number 1 Supplement 1): 4411. doi:10.1182/blood-2023-186099.